1/28
08:00 am
scyx
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
Medium
Report
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
1/21
10:32 am
scyx
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247 [Yahoo! Finance]
Medium
Report
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247 [Yahoo! Finance]
1/21
08:00 am
scyx
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
High
Report
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
12/22
09:07 am
scyx
SCYNEXIS granted Nasdaq extension to regain bid price compliance [Seeking Alpha]
Medium
Report
SCYNEXIS granted Nasdaq extension to regain bid price compliance [Seeking Alpha]
12/22
08:55 am
scyx
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement [Yahoo! Finance]
Low
Report
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement [Yahoo! Finance]
12/22
08:00 am
scyx
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
Low
Report
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
11/19
07:00 am
scyx
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
Low
Report
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
11/17
10:15 am
scyx
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
Low
Report
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
11/12
01:30 pm
scyx
SCYNEXIS (NASDAQ:SCYX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
SCYNEXIS (NASDAQ:SCYX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.